Skip to main content
. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819

Figure 5. Response distribution after the 1st treatment line in patients with and without renal impairment.

Figure 5

Comparing the population treated with novel agents (bortezomib, lenalidomide or thalidomide) to the population treated with conventional agents. (A) Patients with renal impairment. (B) Patients without renal impairment. NR, no response; PR, partial response; ≥VGPR, at least very good partial response.